Anti-thymocyte Globulin (Equine) API Manufacturers

compare suppliers & get competitive offers

teaser-1024x654-1
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Anti-thymocyte Globulin (Equine) is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Anti-thymocyte Globulin (Equine) or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Anti-thymocyte Globulin (Equine) API ?

Description:
Here you will find a list of producers, manufacturers and distributors of Anti-thymocyte Globulin (Equine). You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Anti-thymocyte Globulin (Equine) 
Synonyms:
eATG , equine ATG  
DrugBank number:
DB09312 
Unique Ingredient Identifier:
475247QF1Z

About Anti-thymocyte Globulin (Equine)

What makes Antilymphocyte immunoglobulin (horse) unique? Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The result is polyclonal IgG that is then purified from the horse's serum to produce a usable drug product that can be used for immunosuppression. Although the exact mechanism of action is unknown, equine anti-thymocyte globulin targets a variety of immune system proteins including lymphocyte surface proteins, granulocytes, platelets, bone marrow cells, and other cell types.

Equine ATG is currently indicated for the suppression of the immune system to prevent renal transplant rejection and in the treatment of aplastic anemia. Induction of T cell apoptosis and resulting T-cell lymphopenia found in vivo is credited for its therapeutic effect in these conditions. There are currently various ATG products available, which differ in the source of inoculated animal (rabbit, horse, or pig) and in the type of antigen product used to produce immunoglobulin (thymocytes, peripheral T cells, etc.).

Not sure if this is the exact product you're looking for? Contact the supplier by using the send inquiry button.